Closed and Collaborative

R&D

Closed & Collaborative – January to February 2026

January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

R&D

Closed & Collaborative H2 2025: Mergers, acquisitions, partn...

The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.

Sales & Marketing

Closed & Collaborative H1 2025: Mergers, acquisitions, colla...

The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and biotechnology sectors.

R&D

Merger and acquisition visual concept with buildings and jigsaw

Closed and Collaborative: Mergers, acquisitions, and partner...

As we head further into H2, a final look back to the summer’s industry mergers and acquisiti

R&D

Closed and Collaborative: Mergers, acquisitions, and partner...

Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry

R&D

Collaborative visual illustration, shaking hands in business deal

Closed and Collaborative: Mergers, acquisitions, and partner...

Welcome to a new pharmaphorum round-up.

Closed & Collaborative – January to February 2026

Closed & Collaborative H2 2025: Mergers, acquisitions, partn...

Closed & Collaborative H1 2025: Mergers, acquisitions, colla...

Closed and Collaborative: Mergers, acquisitions, and partner...

Closed and Collaborative: Mergers, acquisitions, and partner...

Closed and Collaborative: Mergers, acquisitions, and partner...

Avalyn seeks $300m from its IPO

Discover a new era of healthcare panel engagement: Grounded ...

Closed and Collaborative

Editor's Picks